ALX Oncology (NASDAQ:ALXO) Earns “Overweight” Rating from Cantor Fitzgerald

ALX Oncology (NASDAQ:ALXO)‘s stock had its “overweight” rating restated by research analysts at Cantor Fitzgerald in a report released on Wednesday,Benzinga reports.

Separately, HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of ALX Oncology in a research note on Wednesday. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $10.67.

ALX Oncology Stock Performance

Shares of ALXO stock opened at $1.79 on Wednesday. The firm has a market cap of $94.41 million, a PE ratio of -0.60 and a beta of 1.04. ALX Oncology has a 12 month low of $1.19 and a 12 month high of $17.83. The company’s fifty day simple moving average is $1.49 and its 200-day simple moving average is $3.40. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07.

Insider Activity

In other ALX Oncology news, Director Rekha Hemrajani purchased 30,000 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was acquired at an average price of $1.55 per share, with a total value of $46,500.00. Following the acquisition, the director now directly owns 33,000 shares of the company’s stock, valued at $51,150. This trade represents a 1,000.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 33.40% of the company’s stock.

Institutional Trading of ALX Oncology

Hedge funds have recently modified their holdings of the stock. Barclays PLC boosted its position in shares of ALX Oncology by 243.6% in the third quarter. Barclays PLC now owns 59,502 shares of the company’s stock valued at $107,000 after acquiring an additional 42,185 shares during the period. XTX Topco Ltd acquired a new stake in shares of ALX Oncology in the third quarter valued at approximately $578,000. Wellington Management Group LLP boosted its stake in shares of ALX Oncology by 15.2% in the third quarter. Wellington Management Group LLP now owns 167,831 shares of the company’s stock valued at $305,000 after buying an additional 22,114 shares during the period. Verition Fund Management LLC grew its position in ALX Oncology by 308.4% during the third quarter. Verition Fund Management LLC now owns 133,025 shares of the company’s stock worth $242,000 after buying an additional 100,454 shares in the last quarter. Finally, Walleye Capital LLC increased its stake in ALX Oncology by 110.3% during the 3rd quarter. Walleye Capital LLC now owns 230,875 shares of the company’s stock worth $420,000 after acquiring an additional 121,113 shares during the period. Institutional investors and hedge funds own 97.97% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.